Genomic DNA at defined integration sites in retinal photoreceptors and retinal pigment epithelium (Retinal gDNA integration sites)

Genomic DNA at defined integration sites in retinal photoreceptors and the retinal pigment epithelium (RPE) serves as the primary therapeutic substrate for precision genome editing and site-specific gene therapy. These specific chromosomal loci are targeted to correct pathogenic mutations or to facilitate the stable integration of functional transgenes in patients with inherited retinal dystrophies (IRDs) [Maeder et al., 2019, Nature Medicine]. Photoreceptors and RPE cells are essential for the conversion of light into neural signals and the maintenance of the visual cycle; thus, genetic defects in these cells lead to progressive blindness. Modern therapeutic strategies, such as CRISPR/Cas9-mediated editing and Homology-Independent Targeted Integration (HITI), utilize these genomic sites to achieve long-term, endogenous gene expression [Suzuki et al., 2016, Nature]. By targeting defined integration sites, researchers aim to overcome the limitations of episomal gene delivery, such as dilution of the transgene over time or lack of physiological regulation. However, the use of genomic DNA as a target necessitates rigorous safety evaluations to prevent off-target mutations and potential genotoxicity [Fu et al., 2013, Nature Biotechnology]. Successful interaction with these sites can lead to significant improvements in visual acuity and retinal sensitivity for patients with previously untreatable conditions.

Other names

Retinal genomic DNAPhotoreceptor DNA integration lociRPE genomic integration sitesTargeted retinal genomic lociRetinal gDNA

Site-specific genomic modification via CRISPR/Cas9-mediated double-strand breaks, homology-directed repair (HDR), or homology-independent targeted integration (HITI) to correct mutations or insert functional transgenes [Suzuki et al., 2016, Nature].